



Precision Medicine development in Gastro-Intestinal Oncology

Evidence based Guidelines using Biomarkers in treatment decision making.
Optimising management and sequencing.

Saturday, 4 July 2020

12:15

CHAIR

Josep Tabernero
Barcelona, Spain

This educational activity is provided by ESMO
and supported by Lilly.



12:15

Introduction

Josep Tabernero, Barcelona, Spain

12:20

**Gastric cancer: Which biomarker to test for?
How could biomarkers help to plan for several
treatment lines? (HER2, MSI, PDL-1, FGFR2,
VEGFR2...)**

Elizabeth Smyth, Cambridge, UK

12:35

**Hepatobiliary carcinomas: How could biomarkers
help select treatments and how can they be used
in later lines (MSI, AFP, PDL-1...)**

Arndt Vogel, Hannover, Germany

12:50

**Metastatic colorectal cancer. Which biomarker
should be routinely tested for (RAS, BRAF, MSI,
ctDNA...) and used in a multi-line setting?**

Michel Ducreux, Villejuif, France

13:05

Conclusions: Take home messages

Josep Tabernero, Barcelona, Spain